FRI0130 A SYSTEMATIC REVIEW OF NATURAL SUPPLEMENTS IN THE TREATMENT OF RHEUMATOID ARTHRITIS
Authors: Y. Liu, J. Pope, M. Turk
Journal: Annals of the Rheumatic Diseases (2020)

Background: Rheumatoid arthritis (RA) is a chronic autoimmune condition affecting almost 1% of the general population (1). Pharmacological management has been the mainstay of treatment for RA and includes DMARDs and biologics. Despite these therapies, anywhere from 28-90% of patients with RA use complementary and alternative medicine (2). These non-pharmacological therapies range from dietary interventions to supplements to nonprescription therapies. Objectives: To determine the efficacy of non-pharmacological, orally-ingested interventions on clinically-relevant endpoints in patients with rheumatoid arthritis. Methods: We systematically reviewed EMBASE and MEDLINE electronical databases from inception until Feb 23, 2019 for relevant articles. Only randomized controlled trials (RCTs) which assessed oral, non-pharmacological interventions (e.g. diets, vitamins, oils, herbal remedies, fatty acids, supplements, etc.) in adult patients with RA, that presented clinically-relevant outcomes (defined as pain, fatigue, disability, joint counts, and/or disease indices) were included. Clinical outcome data was extracted by two independent authors as difference from baseline measurement. Therapies with at least 3 RCTs which presented data on the same clinical outcome were meta-analyzed using a pooled random effects model using RevMan 5. Results: A total of 4423 unique articles were independently assessed by two authors, of which 72 articles met our inclusion criteria. Thirteen different interventions were studied more than once, and six interventions had clinical outcomes reported in at least 3 trials. However, only vitamin D and fatty acids met criteria for meta-analysis. Pooled random effects models suggested vitamin D supplementation improved HAQ scores from baseline (mean difference = -0.10, 95% confidence interval (CI) = -0.17 to -0.02; p=0.01) but had no effect on DAS28 scores (Table 1). Table 1. Mean differences from baseline of various clinical outcomes in RA patients taking vitamin D or fatty acid supplementation compared to control group. Clinical Outcome Total Patients Mean Difference (95% CI) P-value Vitamin D HAQ 573 -0.10 (-0.17 to -0.02) 0.01 DAS28 174 -0.30 (-0.71 to 0.11) 0.15 Fatty Acids TJC 661 -2.05 (-2.83 to -1.27) 0.04 SJC 582 -0.35 (-0.96 to 0.26) 0.26 RAI 234 -1.82 (-4.69 to 1.05) 0.21 Pain 756 -0.61 (-1.02 to -0.20) 0.004 Patient Global 484 -0.26 (-0.59 to 0.07) 0.12 Physician Global 382 -1.08 (-1.98 to -0.18) 0.02 HAQ 277 -0.13 (-0.18 to -0.09) &lt;0.001 DAS28 543 -0.19 (-0.36 to -0.01) 0.03 Fatty acid supplementation improved total joint counts, pain, physician global assessment scores, HAQ, and DAS28 from baseline (Table 1). There were significantly more patients who achieved ACR20 criteria (Relative Risk Ratio = 2.73, 95% CI 1.62-4.58; p&lt;0.001) (Figure 1). Figure 1. Forest plot of studies in which RA patients taking fatty acids achieved ACR20 criteria. https://account-congress.eular.org/Modules/Abstract/Submission/summary.aspx Conclusion: From our meta-analysis, vitamin D and fatty acids supplementation showed statistically significant improvement in some clinical outcomes in patients with RA; however, the degree of improvement is unlikely to be clinically significant. Overall, many trials were of low quality and had high risks of bias including inadequate reporting of data. Further clinical trials that are well-designed and fully powered are still needed to confirm the efficacy of many supplements and diets in RA. References: [1]Myasoedova E, Crowson CS, Kremers HM, Therneau TM, Gabriel SE. Is the incidence of rheumatoid arthritis rising?: results from Olmsted County, Minnesota, 1955-2007. Arthritis Rheum . 2010;62(6):1576–1582. doi:10.1002/art.27425 [2]Efthimiou P, Kukar M, Mackenzie CR. Complementary and alternative medicine in rheumatoid arthritis: no longer the last resort!. HSS J. 2010;6(1):108–111. doi:10.1007/s11420-009-9133-8 Disclosure of Interests: Yideng Liu: None declared, Janet Pope Grant/research support from: AbbVie, Bristol-Myers Squibb, Eli Lilly &amp; Company, Merck, Roche, Seattle Genetics, UCB, Consultant of: AbbVie, Actelion, Amgen, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Eicos Sciences, Eli Lilly &amp; Company, Emerald, Gilead Sciences, Inc., Janssen, Merck, Novartis, Pfizer, Roche, Sandoz, Sanofi, UCB, Speakers bureau: UCB, Matthew Turk: None declared